课题基金 / 基金详情

(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?

(PQD2) Why is Endemic Burkitt Lymphoma Curable with Single Agent Chemotherapy?
(PQD2) 为什么地方性伯基特淋巴瘤可以通过单药化疗治愈?
批准号:
8720728
负责人:
Dirk P Dittmer
金额:
$19.24万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-01 至 2016-08-31

项目摘要

项目成果

Dirk P Dittmer的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): This application is in response to RFA-CA12-022. It addresses PQD - 2 what molecular properties make some cancers curable with conventional chemotherapy? We choose EBV+ endemic Burkitt lymphoma (BL) as the prototypical cancer that is curable with single agent (cyclophosphamide) in >90% of children. This exceedingly high cure rate was already evident in the 1960s in very limited settings (Uganda) and has since been repeated in the US, in Brazil and other nations. Failure is due to co-factors, including socioeconomically and over all performance score, which limit the patients to complete the prescribed number of cycles, rather than molecular heterogeneity. Hence, the reason that this very aggressive cancer is curable is molecular in nature. We will use a functional genetic approach to understand the molecular properties that render BL susceptible to one of the simplest of chemotherapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PQ6: Transgenic Mouse Model for Kaposi Sarcoma
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa
Project 2: Clinical and molecular determinants of HIV-associated Kaposi Sarcoma progression under local standard-of-care therapy in Malawi and South Africa